Journal Article DZNE-2021-00976

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Phenylalanine Effects on Brain Function in Adult Phenylketonuria.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2021
Ovid [S.l.]

Neurology 96(3), e399 - e411 () [10.1212/WNL.0000000000011088]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: To evaluate the relationship between circulating phenylalanine and brain function as well as neuropsychiatric symptoms in adults with phenylketonuria.In this prospective cross-sectional study, early-treated patients with phenylketonuria older than 30 years and age- and sex-matched controls were included. Extensive neurologic evaluation, neuropsychological and behavioral testing, sensory and motor evoked potentials, and MRI were performed. CSF concentrations of neurodegenerative markers were evaluated in addition in a subset of 10 patients.Nineteen patients with phenylketonuria (median age 41 years) with different phenylalanine levels (median 873 μmol/L) entered the study. They showed higher prevalence of neurologic symptoms, cognitive and behavioral abnormalities, autonomic dysfunction, alterations in neurophysiologic measures, and atrophy in putamen and right thalamus compared to controls. In CSF, patients with phenylketonuria exhibited higher β-amyloid 1-42 (p = 0.003), total tau (p < 0.001), and phosphorylated tau (p = 0.032) levels compared to controls. Plasma phenylalanine levels highly correlated with the number of failed neuropsychological tests (r = 0.64, p = 0.003), neuropsychiatric symptoms (r = 0.73, p < 001), motor evoked potential latency (r = 0.48, p = 0.030), and parietal lobe atrophy.Our study provides strong evidence for a correlation between phenylalanine levels and clinical, neuropsychological, neurophysiologic, biochemical, and imaging alterations in adult patients with phenylketonuria.

Keyword(s): Adult (MeSH) ; Atrophy: blood (MeSH) ; Atrophy: diagnostic imaging (MeSH) ; Atrophy: psychology (MeSH) ; Cognition: physiology (MeSH) ; Cross-Sectional Studies (MeSH) ; Evoked Potentials, Motor: physiology (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Magnetic Resonance Imaging (MeSH) ; Male (MeSH) ; Neuropsychological Tests (MeSH) ; Phenylalanine: blood (MeSH) ; Phenylketonurias: blood (MeSH) ; Phenylketonurias: diagnostic imaging (MeSH) ; Phenylketonurias: psychology (MeSH) ; Prospective Studies (MeSH) ; Putamen: diagnostic imaging (MeSH) ; Thalamus: diagnostic imaging (MeSH) ; Phenylalanine

Classification:

Contributing Institute(s):
  1. Parkinson's Disease Genetics AG Berg (AG Berg)
  2. Parkinson Genetics (AG Gasser 1)
  3. Core ICRU (Core ICRU)
  4. Functional Neurogeriatrics (AG Maetzler)
  5. Biobanking Facility Tübingen (Biobanking Facility Tübingen)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2021
Database coverage:
Medline ; Allianz-Lizenz ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > TÜ DZNE > TÜ DZNE-Biobanking Facility (Tübingen)
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Maetzler
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Institute Collections > TÜ DZNE > TÜ DZNE-AG Berg
Institute Collections > TÜ DZNE > TÜ DZNE-ICRU
Public records
Publications Database

 Record created 2021-09-09, last modified 2023-09-15



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)